Filing Flows › Indivior Pharmaceuticals (INDV) › Capital expenditures
Indivior Pharmaceuticals (INDV) capital expenditures by quarter
Indivior Pharmaceuticals' capital expenditures were $14.0M in Q3 2026 (third quarter 2026), +100% from Q2 2026. Over the last 4 quarters it ranged from $5.0M (Q1 2025) to $17.0M (Q2 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $14.0M | +100% | — |
| Q2 2026 | $7.0M | -59% | -59% |
| Q2 2025 | $17.0M | +240% | — |
| Q1 2025 | $5.0M | — | — |
Q3 2026 at a glance
Indivior Pharmaceuticals, Q3 2026: revenue $356M (+13% year over year), operating margin 50.6%, net earnings $137M, operating cash flow $97.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Indivior Pharmaceuticals' capital expenditures?
Indivior Pharmaceuticals' capital expenditures were $14.0M in Q3 2026 (third quarter 2026), +100% from Q2 2026.
How has Indivior Pharmaceuticals' capital expenditures changed?
Over the last 4 quarters it ranged from $5.0M (Q1 2025) to $17.0M (Q2 2025).
Q3 2026 results → · How Indivior Pharmaceuticals makes money →